{
    "nctId": "NCT05748353",
    "briefTitle": "Endocrine Disruptors and Life STILe in Breast Cancer Development",
    "officialTitle": "Endocrine Disruptors and Life STILe in Patients Carrying BRCA Pathogenic VAriants With Breast and/or Ovarian CAncer and Women Without Neoplasm: the STILVARCA Study",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Life Style, Cadmium Exposure",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 275,
    "primaryOutcomeMeasure": "Adherence to mediterranean diet",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age\\>18 years\n* Histologic diagnosis of early-stage BC (stage I, II, III operated; luminal, HER2+, triple-negative tumors) or OC (high-grade epithelial any stage and histotype); presence of germline variant of BRCA1 or BRCA2, class 4 or 5\n* Patients carrying germline variant of BRCA1 or BRCA2, class 4 or 5, in the absence of BC and/or OC, who have not undergone prophylactic mastectomy and/or bilateral ovariectomy surgery.\n* Patients with malignancy must have undergone surgery and be currently disease-free or in complete or partial remission in the case of OC.\n* Adjuvant/neoadjuvant systemic therapy as well as maintenance therapy (PARP-inhibitors for example) is permitted.\n* Signature of informed consent.\n* ECOG: 0.1.\n* Compliance with questionnaire completion\n\nExclusion Criteria:\n\n* Prophylactic breast or ovarian surgery\n* Germinal variant of BRCA1 or BRCA2, class 1,2, 3.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}